Παρακαλώ χρησιμοποιήστε αυτό το αναγνωριστικό για να παραπέμψετε ή να δημιουργήσετε σύνδεσμο προς αυτό το τεκμήριο:
https://hdl.handle.net/10442/17344
Εξειδίκευση τύπου : | Άρθρο σε επιστημονικό περιοδικό |
Τίτλος: | Design of linear and cyclic mutant analogues of dirucotide peptide (MBP 82–98 ) against multiple sclerosis: Conformational and binding studies to MHC class II |
Δημιουργός/Συγγραφέας: | Deraos G. Kritsi E. Matsoukas M.-T. Christopoulou K. Kalbacher H. [EL] Ζουμπουλάκης, Παναγιώτης[EN] Zoumpoulakis, Panagiotis Apostolopoulos V. Matsoukas J. |
Εκδότης: | MDPI AG |
Ημερομηνία: | 2018 |
Γλώσσα: | Αγγλικά |
ISSN: | 2076-3425 |
DOI: | 10.3390/brainsci8120213 |
Περίληψη: | Background: Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system. MS is a T cell-mediated disease characterized by the proliferation, infiltration, and attack of the myelin sheath by immune cells. Previous studies have shown that cyclization provides molecules with strict conformation that could modulate the immune system. Methods: In this study, we synthesized peptide analogues derived from the myelin basic protein (MBP) 82–98 encephalitogenic sequence (dirucotide), the linear altered peptide ligand MBP 82–98 (Ala 91 ), and their cyclic counterparts. Results: The synthesized peptides were evaluated for their binding to human leukocyte antigen (HLA)-DR2 and HLA-DR4 alleles, with cyclic MBP 82–98 being a strong binder with the HLA-DR2 allele and having lower affinity binding to the HLA-DR4 allele. In a further step, conformational analyses were performed using NMR spectroscopy in solution to describe the conformational space occupied by the functional amino acids of both linear and cyclic peptide analogues. This structural data, in combination with crystallographic data, were used to study the molecular basis of their interaction with HLA-DR2 and HLA-DR4 alleles. Conclusion: The cyclic and APL analogues of dirucotide are promising leads that should be further evaluated for their ability to alter T cell responses for therapeutic benefit against MS. |
Τίτλος πηγής δημοσίευσης: | Brain Sciences |
Τόμος/Κεφάλαιο: | 8 |
Τεύχος: | 12 |
Θεματική Κατηγορία: | [EL] Φαρμακευτική χημεία[EN] Pharmaceutical chemistry [EL] Βιοχημεία[EN] Biochemistry |
Λέξεις-Κλειδιά: | Altered peptide ligand Cyclic peptide Dirucotide HLA-DR2 HLA-DR4 MBP MS Multiple sclerosis Myelin basic protein |
Αξιολόγηση από ομότιμους (peer reviewed): | Ναι |
Κάτοχος πνευματικών δικαιωμάτων: | © 2018 by the authors. Licensee MDPI, Basel, Switzerland. |
Όροι και προϋποθέσεις δικαιωμάτων: | All Open Access, Gold, Green |
Εμφανίζεται στις συλλογές: | Ινστιτούτο Χημικής Βιολογίας - Επιστημονικό έργο
|
Αρχεία σε αυτό το τεκμήριο:
Το πλήρες κείμενο αυτού του τεκμηρίου δεν διατίθεται προς το παρόν από τον ΗΛΙΟ.